Genevieve Kanter

Biography

Genevieve P. Kanter, PhD, is Associate Professor of Public Policy at the USC Price School of Public Policy.

She is an economist whose research focuses on the FDA and regulatory issues related to biomedical technologies; financial conflicts of interest; industry relationships and industry influence in medicine; and hospital and physician payment models.

Professor Kanter’s research and essays have been published in leading academic journals, including the New England Journal of Medicine, JAMA, and Health Affairs, and her work and expert commentary have been featured in major media outlets, including the New York Times, Wall Street Journal, Washington Post, Chicago Tribune, AP, NPR, and FiveThirtyEight.

She serves on Medicare Evidence Development & Coverage Advisory Committee (the federal advisory committee for Medicare coverage) and is on the Editorial Board of the journal BMC Medical Ethics.

Professor Kanter received a PhD in Economics and in Sociology from the University of Chicago; completed an NIH postdoctoral fellowship in health and demography at Princeton University; and completed research fellowships in health policy and ethics at Massachusetts General Hospital and Harvard University.

Selected Publications

• Weissman, G.E., Mankowitz, T., & Kanter, G.P. (2025) Unregulated large language models produce medical device-like output. npj Digital Medicine, 8(1), 148.
• Kakani, P., Navangul, S., Lee Luo, C., Tormohlen, K. N., Kanter, G. P., Landrum, M. B., Keating, N. L., & Bond, A. M. (2025). Use of and steering to pharmacies owned by insurers and Pharmacy Benefit Managers in Medicare. JAMA Health Forum.
• Potluri, V. S., Reddy, Y. N. V., Tummalapalli, S. L., Peng, C., Huang, Q., Zhao, Y., Kanter, G. P., Zhu, J., Liao, J. M., & Navathe, A. S. (2024). Early effects of the ESRD treatment choices model on kidney transplant waitlist additions. Clinical Journal of the American Society of Nephrology, 20(1), 124–135.
• Guadamuz, J. S., Alexander, G. C., Kanter, G. P., & Qato, D. M. (2024). More US pharmacies closed than opened in 2018–21; independent pharmacies, those in Black, Latinx communities most at risk. Health Affairs, 43(12), 1703–1711.